Adenosine Deaminase Deficiency

Overview

Plain-Language Overview

Adenosine Deaminase Deficiency is a rare inherited disorder that affects the immune system, which helps the body fight infections. It occurs when the body lacks enough of an important enzyme called adenosine deaminase, leading to a buildup of toxic substances that damage immune cells. This causes a severe form of combined immunodeficiency, making affected individuals highly vulnerable to infections. The condition primarily impacts the lymphocytes, a type of white blood cell essential for immune defense. Without treatment, children with this deficiency often experience frequent, severe infections early in life. The disorder affects the body's ability to protect itself, leading to serious health problems related to infections.

Clinical Definition

Adenosine Deaminase Deficiency is a genetic disorder caused by mutations in the ADA gene resulting in deficient activity of the adenosine deaminase enzyme. This enzyme deficiency leads to accumulation of toxic metabolites such as deoxyadenosine and dATP, which are particularly harmful to lymphocytes, causing profound T-cell, B-cell, and NK-cell lymphopenia. The resulting severe combined immunodeficiency (SCID) manifests as recurrent, life-threatening infections, failure to thrive, and absent or hypoplastic thymus. The condition is inherited in an autosomal recessive pattern and is one of the most common causes of SCID. Early diagnosis is critical due to the high risk of opportunistic infections and mortality without intervention.

Inciting Event

There is no external trigger; disease results from inherited deficiency of ADA enzyme.
Symptoms often become apparent after waning of maternal antibodies in early infancy.
Exposure to common pathogens triggers severe infections due to immunodeficiency.

Latency Period

Symptoms typically develop within the first 3 to 6 months of life as immune function declines.
Newborns are initially asymptomatic due to maternal IgG protection.
Progressive lymphocyte depletion leads to gradual onset of recurrent infections and failure to thrive.

Diagnostic Delay

Early symptoms mimic common infections, leading to misdiagnosis as recurrent viral or bacterial infections.
Lack of awareness and absence of routine newborn screening delay diagnosis.
Immunodeficiency may be attributed to other causes without specific ADA enzyme activity testing.
Failure to recognize characteristic lymphopenia and opportunistic infections prolongs diagnostic delay.

Clinical Presentation

Signs & Symptoms

Recurrent severe infections including bacterial, viral, and fungal pathogens
Chronic diarrhea and failure to thrive in infancy
Oral candidiasis and other opportunistic infections
Pneumocystis jirovecii pneumonia is a common presenting infection
Lymphopenia-related symptoms such as persistent fever and poor wound healing

History of Present Illness

Recurrent, severe bacterial, viral, and fungal infections including pneumonia and otitis media.
Chronic diarrhea and failure to thrive due to malabsorption and systemic illness.
Persistent oral thrush and candidiasis reflecting impaired cellular immunity.
Progressive lymphopenia-related symptoms such as skin rashes and hepatosplenomegaly.

Past Medical History

No prior medical conditions unless previously diagnosed with immunodeficiency.
May have history of recurrent infections since early infancy.
No history of immunosuppressive medications prior to symptom onset.

Family History

Siblings or relatives with early infant deaths from infections suggestive of immunodeficiency.
Consanguineous parents increase risk of autosomal recessive inheritance.
Family history of primary immunodeficiency syndromes or known ADA mutations.

Physical Exam Findings

Lymphopenia with markedly reduced or absent lymphoid tissue such as tonsils and lymph nodes
Failure to thrive and cachexia in infants due to recurrent infections
Chronic diarrhea and oral thrush from opportunistic infections
Hepatosplenomegaly may be present due to immune dysregulation
Eczematous skin rash can be seen in some cases

Diagnostic Workup

Diagnostic Criteria

Diagnosis of adenosine deaminase deficiency is established by demonstrating markedly reduced or absent ADA enzyme activity in red blood cells or leukocytes. Genetic testing confirming pathogenic mutations in the ADA gene provides definitive diagnosis. Laboratory findings include severe lymphopenia affecting T, B, and NK cells, and elevated levels of deoxyadenosine metabolites in blood or urine. Newborn screening programs may detect low T-cell receptor excision circles (TRECs), prompting further evaluation. Confirmatory diagnosis relies on enzyme assay and molecular genetic analysis.

Pathophysiology

Key Mechanisms

Deficiency of adenosine deaminase (ADA) leads to accumulation of toxic metabolites such as deoxyadenosine and dATP.
Elevated dATP inhibits ribonucleotide reductase, impairing DNA synthesis and causing lymphocyte apoptosis.
Severe depletion of T, B, and NK lymphocytes results in profound combined immunodeficiency.
Accumulation of toxic metabolites also causes non-immune systemic toxicity affecting multiple organs.

Involvement	Details
Organs	Lymph nodes are small and underdeveloped due to lymphocyte depletion.
	Spleen is often hypoplastic with reduced lymphoid tissue reflecting immunodeficiency.
	Lungs are susceptible to severe opportunistic infections due to impaired cellular immunity.
Tissues	Bone marrow is affected by toxic metabolites impairing hematopoiesis and lymphoid progenitor cell survival.
Tissues	Thymus tissue is hypoplastic due to impaired T cell maturation and development.
Cells	T lymphocytes are profoundly decreased due to toxic metabolite accumulation impairing lymphocyte development.
	B lymphocytes are also reduced, contributing to combined immunodeficiency and impaired humoral immunity.
	Natural killer cells are decreased, further compromising innate immune defense.
Chemical Mediators	Deoxyadenosine and dATP accumulate due to ADA deficiency, causing lymphotoxicity and apoptosis.
Chemical Mediators	Adenosine deaminase enzyme deficiency leads to toxic purine metabolite buildup disrupting DNA synthesis in lymphocytes.

Treatments

Pharmacological Treatments

Enzyme Replacement Therapy (PEG-ADA)
- Mechanism:
  - Provides exogenous adenosine deaminase to reduce toxic metabolite accumulation.
- Side effects:
  - Injection site reactions
  - Hypersensitivity reactions
  - Transient lymphopenia
- Clinical role:
  - First-line
Hematopoietic Stem Cell Transplantation
- Mechanism:
  - Replaces defective immune cells with healthy donor-derived stem cells restoring immune function.
- Side effects:
  - Graft-versus-host disease
  - Infection risk
  - Organ toxicity
- Clinical role:
  - Curative
Gene Therapy
- Mechanism:
  - Introduces functional ADA gene into patient hematopoietic stem cells to restore enzyme activity.
- Side effects:
  - Insertional mutagenesis
  - Immune reactions
  - Transient cytopenias
- Clinical role:
  - Second-line

Non-pharmacological Treatments

Protective isolation to prevent opportunistic infections due to severe combined immunodeficiency.
Supportive care including immunoglobulin replacement therapy to provide passive immunity.
Nutritional support to maintain growth and development in affected infants.

Prevention

Pharmacological Prevention

Enzyme replacement therapy with pegademase bovine to restore ADA activity
Prophylactic antibiotics and antifungals to prevent opportunistic infections
Immunoglobulin replacement therapy to provide passive immunity
Antiviral prophylaxis in high-risk patients
Hematopoietic stem cell transplantation as definitive treatment

Non-pharmacological Prevention

Avoidance of live vaccines due to immunodeficiency
Strict infection control measures including hand hygiene and isolation
Genetic counseling for families with ADA mutations
Newborn screening for early detection of SCID including ADA deficiency
Nutritional support and growth monitoring to optimize health

Outcome & Complications

Complications

Life-threatening opportunistic infections due to profound immunodeficiency
Chronic lung disease from recurrent infections
Neurological deficits from toxic metabolite accumulation
Failure to thrive and developmental delay
Graft-versus-host disease post bone marrow transplant if mismatched

Short-term Sequelae	Long-term Sequelae
Severe infections requiring hospitalization and intravenous antibiotics Respiratory failure from pneumonia or pneumonitis Sepsis due to overwhelming infection Electrolyte imbalances from diarrhea and malabsorption Acute respiratory distress syndrome (ARDS) in severe pulmonary infections	Chronic lung disease with bronchiectasis Neurodevelopmental delay due to metabolic toxicity Growth retardation and failure to thrive Chronic autoimmune disorders secondary to immune dysregulation Increased risk of malignancies such as lymphoma

Differential Diagnoses

Adenosine Deaminase Deficiency versus X-linked Severe Combined Immunodeficiency (SCID)

Adenosine Deaminase Deficiency	X-linked Severe Combined Immunodeficiency (SCID)
Autosomal recessive inheritance affecting both sexes equally	X-linked recessive inheritance affecting mostly males
Profound deficiency of T, B, and NK cells (T−B−NK−)	Absent or severely reduced T cells with normal or elevated B cells (T−B+NK+ or T−B+NK−)
Mutation in the ADA gene causing toxic metabolite accumulation	Mutation in the IL2RG gene encoding the common gamma chain

Adenosine Deaminase Deficiency versus RAG1/RAG2 Deficiency (Omenn Syndrome)

Adenosine Deaminase Deficiency	RAG1/RAG2 Deficiency (Omenn Syndrome)
Severe combined deficiency of T, B, and NK cells (T−B−NK−)	Presence of oligoclonal, autoreactive T cells with absent B cells (T+B−)
Severe infections without autoimmune manifestations	Erythroderma, lymphadenopathy, hepatosplenomegaly with autoimmune features
Deficiency of adenosine deaminase enzyme activity	Mutations in RAG1 or RAG2 genes impairing V(D)J recombination

Adenosine Deaminase Deficiency versus Purine Nucleoside Phosphorylase (PNP) Deficiency

Adenosine Deaminase Deficiency	Purine Nucleoside Phosphorylase (PNP) Deficiency
Elevated deoxyadenosine and dATP levels with normal uric acid	Elevated inosine and guanosine metabolites with low uric acid
Profound combined T, B, and NK cell deficiency	Predominant T-cell immunodeficiency with normal or mildly reduced B cells
Mutation in ADA gene causing enzyme deficiency	Mutation in PNP gene causing enzyme deficiency

Adenosine Deaminase Deficiency versus Chronic Granulomatous Disease (CGD)

Adenosine Deaminase Deficiency	Chronic Granulomatous Disease (CGD)
Severe lymphopenia affecting T, B, and NK cells	Normal lymphocyte counts with defective neutrophil oxidative burst
Recurrent infections including opportunistic pathogens like Pneumocystis jirovecii	Recurrent infections with catalase-positive bacteria and fungi (e.g., Staphylococcus aureus, Aspergillus spp.)
Low or absent adenosine deaminase enzyme activity	Abnormal dihydrorhodamine (DHR) test showing defective neutrophil respiratory burst

Adenosine Deaminase Deficiency versus Common Variable Immunodeficiency (CVID)

Adenosine Deaminase Deficiency	Common Variable Immunodeficiency (CVID)
Presents in infancy or early childhood	Typically presents in late childhood or adulthood
Profound combined T, B, and NK cell lymphopenia	Normal T-cell numbers with low immunoglobulins and impaired antibody responses
Severe, life-threatening infections early in life without autoimmunity	Recurrent sinopulmonary infections with variable severity and autoimmune complications